The FDA’s approval of an mRNA flu shot presents a new, long-awaited option
An mRNA flu vaccine is on its way.On August 5, the U.S. Food and Drug Administration approved Moderna's mFlusiva, the first
influenza vaccine to use mRNA technology, for adults 50 and older.
The approval gives many older Americans a long-awaited new
option for protection. Tens of thousands of Americans typically die from the
flu every year, and the vast majority of them are 65 and older.
It’s long been a public health priority to evolve flu
vaccine technology—a process which currently takes more than six months to
produce a shot and is prone to mismatches with the circulating strains—so that
manufacturers can respond more quickly to the evolving virus, ultimately making
flu shots more effective.
When it comes to those goals, Moderna’s mRNA shot is “very, very promising,” says Anna Durbin, MD, a professor in International Health and director of the Center for Immunization Research.
“Most vaccinologists believe that mRNA vaccines are the
future,” says Durbin, who sits on the FDA panel that recommended the
vaccine. Regulators in the EU, Canada, and Australia are also reviewing the
vaccine, and the European Medicine Agency has separately authorized a
combined mRNA COVID-flu vaccine, also by Moderna.
For now, Durbin says, the FDA approval provides a welcome
new option for older Americans—but the price, demand, and availability of the
shot, and what it means for existing vaccines, remain open questions.

















.webp)



